VERA250117P45000
- 2.40
- 0.000.00%
Vera Therapeutics Newsroom
Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing
Vera Therapeutics (VERA) Receives a Buy From TD Cowen
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (VERA) Gets a Buy From J.P. Morgan
Wells Fargo Initiates Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $70
Express News | Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Express News | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Vera Therapeutics Partners With University of Michigan on the NEPTUNE Match Project and PIONEER Study
Vera Therapeutics Price Target Raised to $38.00/Share From $30.00 by Wedbush
Vera Therapeutics Is Maintained at Neutral by Wedbush
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75
Vera Therapeutics to Participate at Upcoming Investor Conferences
Express News | Vera Therapeutics Inc : Guggenheim Cuts Target Price to $59 From $64
Vera Therapeutics Advances in Autoimmune Treatment
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Vera Therapeutics | 10-Q: Q3 2024 Earnings Report
Vera Therapeutics: Strong Buy Rating Backed by Financial Stability and Promising Atacicept Data
Express News | Vera Therapeutics: Believes Balance Sheet Sufficient to Fund Ops Through Potential Approval, U.S. Commercial Launch of Atacicept